

IN THE CLAIMS

1. (currently amended) A method of inhibiting inflammation in ~~a host~~ an *in vitro* model, the method comprising:

contacting said ~~host~~ *in vitro* model with an effective dose of a compound that inhibits integrin linked kinase (ILK) as set forth in SEQ ID NO:1.

2-3. (canceled)

4. (currently amended) The method according to Claim 1, wherein said ~~inhibitor~~ compound comprises a small organic molecule.

5. (original) The method according to Claim 4, wherein said molecule blocks ILK catalytic activity.

6. (currently amended) The method according to Claim 1, wherein said ~~inhibitor~~ compound decreases the available level of [PtdIns (3,4,5) P<sub>3</sub>] in a cell.

7. (currently amended) The method according to Claim 6, wherein said ~~inhibitor~~ compound is wortmannin.

8. (currently amended) The method according to Claim 6, wherein said ~~inhibitor~~ compound is LY294002.

9. (original) The method of Claim 1, wherein cellular migration is inhibited.

10. (currently amended) A method of preventing inflammation in ~~a host~~ an *in vitro* model, the method comprising:

contacting said ~~host~~ *in vitro* model with an effective dose of a compound that inhibits integrin linked kinase (ILK) as set forth in SEQ ID NO:1.

11-12. (canceled)

13. (currently amended) The method according to Claim 10, wherein said ~~inhibitor~~ compound comprises a small organic molecule.

14. (original) The method according to Claim 13, wherein said molecule blocks ILK catalytic activity.

15. (currently amended) The method according to Claim 10, wherein said ~~inhibitor~~ compound decreases the available level of [PtdIns (3,4,5) P<sub>3</sub>] in a cell.

16. (currently amended) The method according to Claim 15, wherein said ~~inhibitor~~ compound is wortmannin.

17. (currently amended) The method according to Claim 15, wherein said ~~inhibitor~~ compound is LY294002.

18. (original) The method of Claim 10, wherein cellular migration is inhibited.